Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

[1]  J. Lunceford,et al.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. , 2017, The Lancet. Oncology.

[2]  P. Sharma,et al.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial , 2016, The Lancet. Oncology.

[3]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[4]  T. Curiel,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[6]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[7]  Donnell,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Mariani,et al.  Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[10]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[11]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[12]  J. Taube,et al.  Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. , 2015, Urology.

[13]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[14]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[15]  Xiaoping Su,et al.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer , 2014, Nature Reviews Urology.

[16]  G. Sonpavde,et al.  Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. , 2014, Clinical genitourinary cancer.

[17]  C. Ortmann,et al.  Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. , 2013, Future oncology.

[18]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Kantoff,et al.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Sonpavde,et al.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[23]  S. Boorjian,et al.  T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival , 2008, Clinical Cancer Research.

[24]  M. Neary,et al.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.

[25]  Haidong Dong,et al.  PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.

[26]  J. Hainsworth,et al.  Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium , 2005, Cancer.

[27]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[30]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .